Guillain-Barr é syndrome in COVID-19: A scoping review

Authors: Imran Ahmad, 1 Faroog Azam Rathore2

¹ Associate Professor, Department of Neurology, Bahria University Medical and

Dental College, Bahria University, Karachi, Pakistan drimran72@yahoo.com

² Assistant Professor, Department of Rehabilitation Medicine, Bahria University

Medical and Dental College, Bahria University, Karachi, Pakistan

faroograthore@gmail.com

Corresponding Author

Faroog Azam Rathore, Assistant Professor, Department of Rehabilitation Medicine.

Bahria University Medical and Dental College, Bahria University, Karachi, Pakistan

faroograthore@gmail.com

Word count: (excluding references and Tables): 3572

Word Count (Abstract): 287

Number of Tables: 03

Number of Figures: 0

Sources of support: Nil

Conflict of interest: None

Acknowledgements: Nil

Abstract

Introduction

The novel corona virus (COVID19) can result in several neurological complications. Guillain-Barré Syndrome (GBS) is one of them and has been reported from different parts of the world in this pandemic. It is an acute post infectious polyneuropathy. The review aims to summarize the demographic features, clinical presentation, diagnostics workup, and management strategies of COVID-19 associated GBS reported in literature.

Material and method

We searched Medline, PubMed Central, SCOPUS and Google Scholar using predefined keywords, with no time limits and in English language only. We aimed to include all kind of manuscripts. Last search was done on 18th May 2020.

Demographics, clinical features, diagnostic workup, management, and outcomes were documented in the data sheet.

Results

We identified 24 cases of COVID-19 associated GBS. Most of the cases were reported from Italy followed by USA. Majority were males (18 /24) The age ranged from 23 -84 years. The clinical presentation was typical sensory-motor GBS in most. Nine patients had facial palsy of which five had bilateral involvement. Two patients had bilateral abducent nerve palsy while two presented as paraparetic GBS variant with autonomic dysfunction. Electrodiagnostics was performed in 17 patients only and 12 had typical features of acute inflammatory demyelinating polyneuropathy.

Intravenous immunoglobulins were the preferred mode of treatment in most of the

patient. There was one death, and most were discharged to rehabilitation or home.

Conclusion

GBS is a frequent neurological complication associated with COVID-19. There is no

clear causative relationship between GBS, and COVID-19 at present and more data

are needed to establish the casualty. However, most cases have a post-infectious

onset with male preponderance. Most of the cases have a typical presentation but

some may present in an atypical way. Prognosis is generally good.

Keywords: Neurology, Clinical features, Coronavirus, GBS, Polyneuropathy,

Paraparesis, Rehabilitation

Introduction

The novel coronavirus (COVID19) infection originated from Huanan seafood market in Wuhan city China in December 2019. It rapidly spread to more than 200 countries of the world with 7 million confirmed cases and more than 400,000 fatalities as of 10^{st} June 2020. COVID-19 primarily affects the respiratory tract and the lungs. However, involvement of cardiovascular, renal system and neurological system has also been reported. The reported neurological manifestations and complications of COVID-19 include anosmia, headaches, dizziness, delirium, stroke, epilepsy, encephalitis, encephalopathy, myalgias and Guillain-Barr é syndrome (GBS) 2 , At present, there are no reviews, full length research article or reports discussing a specific neurological complications in detail.

The objective of this review is to summarize the important demographic features, clinical presentation, diagnostics, and management strategies of COVID-19 associated GBS reported in literature so far. We aim to inform the readers about this important neurological manifestation of COVID-19 in order to formulate better diagnostic and management strategies.

Historical Perspectives on Guillain-Barr é syndrome

The mysterious link between infections followed by paralysis has intrigued physicians for centuries.⁵ Although this relationship was mentioned by the famous Muslim physician Avicenna centuries ago and many other authors published their cases too, but the detailed description of the disease, including nerve conductions studies and cerebrospinal fluid analysis with albuminocytological disproportions was first documented by three French physicians Georges Guillain, Jean Alexandre Barr´, and Andr´e Strohl, who were working together at the Neurological Center of

Pathophysiology and Clinical Features of Guillain-Barr é syndrome

GBS is acute onset immune mediated disorder characterized by rapidly progressive limbs and bulbar weakness which can lead to respiratory failure. ⁷

Many triggers for GBS have been identified including bacterial and viral infections, surgery, and pregnancy. The link of GBS with vaccination is controversial.

Respiratory and Gastrointestinal infections constitute two third of cases. The molecular mimicry between the cell membrane antigen of microbe and ganglioside component of nerve antigen misdirects the immune response. This immune response is humoral mediated and not T cell mediated. The prototype example is of Campylobacter Jejuni infection. The carbohydrate moiety of liopooligosacchrides of Campylobacter Jejuni is capable of inducing antibodies that cross react with glycans present on nerve gangliosides. The exact trigger to mount this misdirected immune response is still not known. There is no specific genetic predisposition as only 1% of all campylobacter infections will result in GBS. GBS has also been reported after viral infections for example Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, and Chikungunya virus:12.8

The clinical hallmark is hyporeflexia or areflexia. The course of the disease is monophasic. Recommended treatment for GBS includes plasmapheresis (PLEX) and immunoglobulins (IVIG) infusion.⁹ GBS was initially described only as a

demyelinating polyneuropathy. Typical features of demyelination on electrodiagnostic studies (EDX) include prolong distal latencies, reduction of conduction velocity, prolong F-waves, temporal dispersion, and conduction block. Clinically many different variants with distinct clinical and electrophysiological features have been reported in literature², ¹⁰. These include, cranial, autonomic, ataxic, paraparetic and mixed variety. The GBS reported from North America and Europe is predominantly demyelinating type while in Asian countries the axonal type of GBS constitutes 30-50 % of the reported cases. ^{11,12,13,14} The mortality of GBS reported from European and North American studies ranges from 3-7%, and is mainly due to respiratory failure, deep vein thrombosis and autonomic dysfunction. The axonal variants of GBS mostly reported in the Chinese and Asians populations have a poor prognosis. ¹⁵ The poor prognosis is because peripheral nerve remyelination is a natural and active process. Whereas in case of axonal variant of GBS, once the axonal integrity is damaged, it does not be regenerate actively and completely.²

SARS-CoV-2 belongs to the broad family of Coronaviruses sub-family beta Coronaviruses ¹⁶. These are enveloped, single-stranded RNA viruses with a diameter of approximately 60–140 nm. The viral envelope has four structural proteins known as S (spike), E (envelope), M (membrane), and N (nucleocapsid). It is the interaction with the spike protein and host cell receptor which is essential for virulence and infectivity.¹⁷

Neurological injury due to Coronavirus

Coronaviruses are not primarily neurotropic viruses and their primary target is respiratory and cardiovascular systems. It is through the Angiotensin-converting enzyme 2 (ACE-2) receptors the virus is attached to host cells leading to internalization and subsequent viral replication. This receptor is also found in glial cells in the Central Nervous System (CNS) and spinal neurons. Very rarely the virus can invade peripheral nerves and lead to retrograde transfer via synapse mediated route to CNS. Another proposed route of entry is through the olfactory nerves. ¹⁸, ¹⁹ Past experience with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory syndrome (MERS) related cases has also provided insights into the neuro invasive potential of Coronaviruses.²⁰, ²¹ As the number of COVID-19 cases with neurological manifestations and complications are being reported more frequently, there is growing evidence for neurotoxic potential of COVID-19. This neurotoxicity can occur as a result of direct or indirect insult by virus and may manifest in form of post-infectious complications like GBS. In this review we will focus only on the post infectious complication only.

COVID-19 does not directly invade peripheral nerves, nerve roots, or anterior horn cells leading to inflammation and death of motor neurons as seen in polio virus or West Nile virus. Even the Cerebrospinal fluid (CSF) Polymerase chain reaction (PCR) for coronavirus in multiple reported cases of COVID-19 related GBS has been negative.²² It is likely a post infectious or may be a para-infectious complication resulting from an aberrant immune response. During the inflammatory phase numerous mediators of inflammation are released from activated leukocytes including Interleukin-6 (IL-6), named as Cytokine storm. This can result in major organ damage, rapid deterioration of the patient and ultimately death.²³ However, due to lack of experimental data It is difficult to deduct if IL-6 is also responsible for the c is also causing neurological damage ³⁷ After the acute phase of the infection, an immune response is generated by the host and may lead to a misdirected response against host epitopes. It can result in an autoimmune, response directed against peripheral nerves and nerve roots in susceptible individuals. This may be either demyelinating or axonal degeneration type. This results in a typical GBS like presentation in the peripheral nerves and spinal roots. However, due to lack of clear data, there is still not enough evidence available to conclude if antibodies to any specific ganglioside antigen are present in these cases or not.

We searched Medline, PubMed Central, SCOPUS and Google Scholar using keywords "COVID-19", "Coronavirus", "Coronavirus Infections", "Coronaviridae", "2019 nCoV". "pandemic", "SARS-COV-2", "neurology", "neurological", "complications", "manifestations", "Guillain-Barr é syndrome", "GBS", "acute inflammatory demyelinating polyneuropathy"," Demyelinating Polyradiculoneuropathy", "polyneuropathy", and "Miller Fisher syndrome". Different combinations of Boolean logic (AND, OR and NOT) were used to identify relevant articles. Search was limited only to English language manuscripts with no time limit. It is important to note that new data is being shared regularly and so far, it consists mostly of pre-prints, letters to editor, single case reports, small case series, and part of an article describing clinical features of COVID-19. Most of the data on COVID-19 at present is published from countries most severely affected, including China, Italy, Spain, and USA. The last literature search was done on 18th May 2020. At that time there was no specific research article, systematic or narrative review describing COVID-19 associated GBS. However, we identified two systematic reviews protocols on this topic registered in the International prospective register of systematic reviews. 24,25

Both authors independently performed the literature search and compared the results for any major discrepancies. The information was extracted on a predesigned data sheet. The items of interest were the demographic data, presenting features, clinical examination, laboratory and radiological investigations, treatment protocol and outcomes. Due to the limited number of cases and nature of the review,

a quantitative analysis was not done, and we have only provided a qualitative review of the retrieved information.

Results

Characteristics of included studies

After removing the duplicates, non-English manuscripts, and unrelated articles, we identified 24 cases of GBS in COVID-19, published in the English biomedical literature till 18th May 2020. These were published as letter to editor, case reports or case series. The results are summarized in the Tables 1 and 2.

Demographics

Most of the cases (8) were reported from Italy ^{26,27,28,29} followed by the USA (4 cases)^{30,31,32} Iran (3 cases),³³,³⁴ Spain (3 cases),³⁵, ³⁶ Germany (2 cases) ^{37,38} and one case each from China ³⁹, France ⁴⁰, Switzerland ⁴¹ and Morocco. ⁴² Majority of the patients were males (18 /75%). The age ranged from 23-84 years and mean age is 60 years.

Clinical Features

Most of the patients (17/24) had typical presenting features of GBS with sensory paresthesia followed by ascending paralysis. Three patients had Miller Fisher variant presenting as ataxia, ophthalmoplegia and areflexia. Total of nine patient developed facial palsy out of which six had bilateral facial palsy. One case had only bilateral facial palsy without any peripheral manifestations and was labeled as facial diplegic variant of GBS. Two patients developed bilateral six nerve palsy. One patient among above who initially presented with bilateral facial and hypoglossal palsy and progressed to a locked in syndrome like condition. One case each from the US³¹ and Switzerland ⁴¹ initially presented with paraparesis and bladder and bowel

dysfunction. Spinal cord imaging was normal in both these cases and these were labeled as paraparetic variant with autonomic dysfunction.

An important peripheral nervous manifestation i.e. hyposmia and hypogeusia was reported in Five patients. One of them had complete reversal of hyposmia at the time of discharge. The predominant clinical presentation in majority of the cases was post-infectious. However, in three cases the onset of symptoms suggested a parainfectious course of disease.

Laboratory and Radiological Investigations

Nasopharyngeal swab samples of all cases were PCR positive for COVID-19, except one case. That patient repeatedly tested negative but, later his serology tested positive for COVID-19. CSF PCR for COVID-19 was tested in twelve patients and it was negative in all. Ganglioside antibody was tested in twelve cases. It was positive in two case only. One of them was the Miller Fisher Variant. CSF analysis performed in 20 cases. Four patients had a normal CSF analysis while in 16 cases it showed albuminocytological disproportion of GBS.

An important finding was that revealed COVID-19 associated lung changes on High-Resolution Chest Tomography (HRCT) chest in fourteen cases. X-ray chest was normal in six cases and revealed pneumonia in one case. Chest imaging was not reported in two cases. This can potentially guide the clinicians. During this pandemic, in a GBS patient HRCT chest should be ordered in case of any doubt to detect possible COVID-19 associated pneumonia as both can be contribute towards respiratory failure.

Nerve conduction studies/ Electromyography (NCS/EMG) were performed in 17 cases. Out of these twelve cases had prolong distal latencies (DML) and absent F waves suggestive of a typical demyelinating polyneuropathy. Four cases had Acute Motor and Sensory Axonal Neuropathy (AMSAN) variant and one had Acute Motor Axonal Neuropathy (AMAN) variant of GBS. However, in the Italian case series, the author reported their NCS/EMG as a mixed picture whereas a prolong DML and absent F waves favors a demyelinating variant.²⁸

Treatment

Three cases were ambulatory with minimum motor deficit and were not offered any treatment for GBS. One of them was a Miller Fisher variant. Nineteen patients were given IVIG. Among these two cases had repeat sessions of IVIG and two cases had PLEX after IVIG due to initial inadequate response. Two case had PLEX sessions as primary treatment one among them had IVIG after PLEX also.

Outcomes and discharge status

One case expired due to complications. Nine patients were either discharged to nursing homes or shifted to rehabilitation for exercise. Complete recovery was reported in eight patients. At the time of publication of cases, three patients were on mechanical ventilation, one was critically ill, and no improvement was reported in one case. Outcome and discharge status were not mentioned for three cases.

Discussion

This review suggests that COVID-19 associated GBS has emerged as an important neurological manifestation and complication of this global pandemic. Although, a clear association of COVID-19 leading to triggering of GBS is lacking at present, past experience with Zika Virus associated GBS suggests a possibility of causality between GBS and COVID-19 infection.

The onset of GBS was post infectious in all the cases in this review, except three in which it was para infectious. A similar pattern has also been seen in Zika Virus infections. Therefore, the treating physician should have a high index of suspicion in managing such cases. The patient might be in the infective stage of COVID-19 and proper barrier precautions will be necessary for the safety of hospital staff. Lung changes due to COVID-19 infection were see in a large number of patients in this review (15/24). Fourteen had a positive HRCT and one had pneumonia on X ray chest. All of these cases had a positive Nasopharyngeal PCR. Therefore, it is important to consider that during the current pandemic respiratory compromise in GBS may not be entirely due to neuromuscular failure but may also be due to COVID-19 pneumonia. At the same time if the patient with COVID-19 is having deterioration of respiratory function or is difficult to wean from ventilator GBS should also be considered as one of the possible reason.

This review suggests that in COVID-19 associated GBS, AIDP variant is more common followed by AMAN and AMSAN variants. However, Umapathi has recently suggested that Covid-19 GBS might be axonal due to paranodal pathologies and follow up EDX might help in reaching to a conclusion.⁴³ Three patients presented

with Miller Fisher syndrome variant which is a large number considering the very low incidence of Miller Fisher syndrome variant of GBS in general population.

The experience with Zika virus related GBS suggests that the patient present with typical symptoms including facial palsy on presentation, male predominance, and AIDP on EDX. A similar pattern was documented in this review. In a review from Puerto Rico facial weakness was seen in 62% cases of Zika Virus associated GBS as compared with 10% in non- Zika related GBS⁴⁴. In this review 37.5 % of the cases had facial weakness with 5 having bilateral facial paralysis. The incidence of dysphagia in Zika Virus associated GBS has been reported to be 53.5% while it is very low in COVID-19 associated GBS (5/24 (20%).

Two patients had paraparesis at presentation followed by urinary retention and were later diagnoses as GBS. ^{31,41} This paraparetic pattern is seen more commonly in Zika Virus associated GBS cases. We do not know the exact mechanism of this phenomenon.

In 5 cases hyposmia and hypogeusia were either the presenting or co-existing features. ^{29,35} These were likely due to the COVID-19 infection and not because of GBS. This is an important finding and can be used as a clinical indicator of COVID-19 infections in suspected GBS cases.

Seropositivity of GBS for ganglioside antibody is reported to be around 30% with the cases of MFS having 95% GQ1b positivity. In this review only one case was positive GD 1b ganglioside antibody. However, this data is too small to make a conclusion Most of the cases in this review were treated with 5 sessions of IVIG. In two cases, IVIG was repeated while in two cases PLEX was also done after giving IVIG. PLEX

has been used in two cases as initially and in one it was followed by IVIG due to inadequate response. One of the possible reasons for use of frequent use of IVIG in all these cases is that all of them were in high income countries with adequate resources and easy access to IVIG. We would like to suggest that in resource constrained areas and the developing world PLEX might prove to be equally beneficial as this is the preferred mode of treatment in cytokine storm syndrome due to COVID-19.

Most of the patients had a good outcome and were either discharged to home with complete recovery or were referred to rehabilitation for management of residual weakness and motor deficits. There was one death and four patients were reported to be on mechanical ventilation at the time of publication of the case reports. However, due to the limited data, it is difficult to comment if COVID-19 associated GBS increases severity of illness, length of Intensive care Unit (ICU) admission and prolongs ventilatory support.

Comparison of MERS associated GBs Vs. and COVID-19 associated GBS

The published data regarding neurological complication and manifestations associated with MERS is limited. 45, Error! Bookmark not defined. 47 In addition, MERS was an epidemic limited to one geographic area and GBS associated with MERS was rarely reported so it is not possible to make a detailed comparison between this and COVID-19 associated GBS due to paucity of data. There is one case report of a critical illness neuropathy due to prolong intensive care unit stay reported from Saudi Arabia. 46 Kim et.al identified only four cases from Korea during the 2015 our break of MERS, which presented with neurological features. 45 One was diagnosed as GBS Bickerstaff variant, second one as Intensive care unit associated neuropathy overlapping with GBS and last 2 were labeled as toxic neuropathy. All four had sensory features on presentation and one of them developed motor weakness and ophthalmoplegia. However, EDX evaluation and CSF examination was normal in all patients. Ganglioside antibody was also negative. Only one patient required mechanical ventilation and was given IVIG. The other three did not have motor weakness and were only kept under medical observation, provided supplemental oxygen and no specific treatment was offered. These epidemics limited to a specific geographic zone affecting only 2494 people (WHO estimates), unlike COVID-19 which is a global health care crisis affecting millions. However, the common feature among both is the craniobulbar involvement in both. ⁴⁷ See Table 3

Comparison of Zika Virus associated GBS Vs. COVID-19 associated GBS

The comparison of COVID-19 associated GBS with Zika Virus associated is presented in Table 3. In Zika Virus-GBS the median time from symptoms to disease onset was seven days consistent with para infectious GBS whereas in this review the median time was 11 days (3-28) days. In Zika Virus GBS the disease was more aggressive with frequent ICU admission and need for ventilatory support. Our data reports a similar pattern with a total of nine patients needing respiratory support. Seven were placed on mechanical ventilation and two were on noninvasive ventilation. On EDX evaluation demyelinating type is the most finding both with =Zika Virus and COVID-19 associated GBS. Cranial involvement is another feature common to both types of GBS.

Limitations

Despite a rigorous search methodology for this review, we were not able to perform literature search all the major English bio-medical literature search databases due to lack of resources and access. There is a possibility that we might have missed some cases which we hope will be identified in the systematic reviews registered in the International prospective register of systematic reviews. The total number of confirmed cases of COVID-19 globally is now more than 7 million but we were able to document only 24 cases of GBS reported in the English biomedical literature so far. This is a very small number of cases to make a causal relationship or a definitive conclusion regarding COVID-19 associated GBS. Due to the wide spread of the disease and wide variations in the documentation and reporting of data from different parts of the world, there are chances that mild cases of GBS or cases with limited involvement might be missed or do not report to hospitals. Moreover, neurological services are not widely available in many developing countries and there is a possibility that some COVID-19 associated GBS cases remain undiagnosed due to lack of expertise in neurology. In addition, mortality in COVID-19 cases due to rapidly progressive respiratory failure is usually attributed to the COVID-19 itself. There is a possibility of co-existing GBS which may contribute to the worsening of the condition. We hope that as more data from different parts of the world is shared, things will become clearer in future and provide further insights into the COVID-19 associated GBS..

The primary presentation of COVID-19 is respiratory but neurological manifestations and complications are increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed to establish the casualty. However, from the available data we conclude that most of the cases present as a post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate better care plans in future.

Table 1: Details of the Demographics and clinical features of COVID-19 related GBS

	Country	Author	Age	Gender	Presenting symptoms	Clinical Examination	H/o Respiratory or GIT	Travel history
			(Years)				infection	
1.	China	Zhao	61	Female	Acute weakness both legs,	Symmetrical weakness grade 4/5 on	Develop fever and cough on	Travel to Wuhan City, China
					Severe fatigue	MRC Scale	eight day of illness.	
						Areflexia		
						After three days power 3/5 legs		
						Sensations decreased to light touch in		
						feet		
2.	Iran	Sedaghat	65	Male	Started from lower limbs	UL Muscle Power 2/5 proximal and	Cough, Fever, and dyspnea	Not Reported
					Five days upper limbs involved	3/5 distal	02 weeks prior to admission	
					symmetrical ascending	LL Muscle Power 1/5 proximal and 2/5		
					quadriparesis,	distal		
					Bilateral facial palsy	Areflexia		
						Impaired vibration and proprioception		
						distally (DM)		
3.	France	Camdessa	65	Male	paresthesia hands and feet	2/5 in legs and arms proximally. 3/5	Cough and fever 11 days	No
		nche			progressed to Quadriplegia in	forearm and 4/5 hand	before admission	
					3 days	Areflexia		
						Absent vibrations		
						Dysphagia present		
4.	USA	Virani	54	Male	Numbness and weakness.	Power 4/5 LL initially	Fever at presentation.	No

					followed by Urinary retention and ascending paralysis	Progressed to 2/5 Areflexia	Cough for 10 days	
5.	Spain case 1	Gutiérrez	50	Male	Vertical diplopia, Gait instability, perioral paresthesia Headache	Ataxia and Areflexia Right INO, Right 3 rd nerve palsy No facial weakness Anosmia and ageusia	Five days back Fever, cough Malaise and backache	No
6.	Spain case 2	Gutiérrez	39	Male	Diplopia and ageusia	Bilateral abducent palsy Areflexia No ataxia and Gait instability	Fever and diarrhea 3 days before admission. No respiratory symptoms No respiratory symptoms	No
7.	Italy	Toscano,	77	Female	Paresthesia in lower limbs and hands, Acroparesthesia and hypogeusia	Flaccid quadriplegia Areflexia Later on dysphagia and respiratory difficulty	Fever and cough 7 days before admission	No
8.	Italy	Case 2	23	Male	Facial weakness, mastoid pain and lower limb paresthesia	Hypogeusia Areflexia Bilateral facial palsy Sensory ataxia	Fever and sore throat for 10 days before admission	No
9.	Italy	Case 3	55	Male	lower limb weakness, Paresthesia, and neck pain	Areflexia Quadriplegia bilateral facial palsy	Fever and cough for 10 days before admission.	No

10	Italy	Case 4	76	Male	Back pain, lower limb	Areflexia	Dry cough for five days	No
					weakness and anosmia	Quadriparesis	before admission and	
							weakness on ninth day	
11	Italy	Case 5	64	Male	Cough, asthenia, hyposmia and	Areflexia paraparesis later on	Cough seven days before	No
					hypogeusia I followed by	Quadriplegia, facial palsy, bulbar	onset of neurological	
					proximal weakness and	weakness and dysphagia	symptoms	
					paresthesia			
12	Italy	Alberti	71	Male	Paresthesia, Distal weakness	Symmetric limb weakness 2/5 LL and	Fever for few days in the	Not Reported
					progressing to quadriparesis in	3/5 UL.	previous week	
					3 days	Glove and stocking paresthesia and		
						Areflexia		
13	Italy	Padroni	70	Female	Paresthesia	4/5 power	24 days back fever and	No
					Asthenia and gait difficulty	Areflexia	cough	
						Sensations intact		
14	USA	Dinkin	36	Male	Bilateral distal Leg Paresthesia	Left eye ptosis	Fever, cough and myalgias	Not Reported
					and diplopia	Mydriasis and partial 3 rd nerve.	four days before admission.	
						Bilateral abducent palsy		
						Gait ataxia, hypoesthesia and		
						areflexia		
15	Switzerla	Ceon	70	Male	Paraparesis. allodynia, Myalgia,	Bilateral lower limb Flaccid	Myalgia, fatigue, dry cough	No
	nd				Difficulty in voiding and	paraparesis	10 days before admission	
					constipation	Areflexia in all limbs		
						Planters down going		

16	Morocco	Otmani	70	Female	Tingling and rapidly progressive	Areflexia and quadriplegia	Dry cough and fever three	Not Reported
					weakness		days before admission total	
							10 days before first symptom	
17	Italy	Ottaviani	66	Female	Difficulty walking and fatigue.	Initially symmetric paraplegia	Mild fever and cough 10	Yes
					Rash on hands	UL power 4/5	days before presentation	
						Unilateral facial palsy		
						areflexia		
18	Germany	Pfefferkorn	51	Male	Progressive upper and lower	2/5 Muscle power with Quadriplegia	Fever and flu, 02 weeks ago.	Not Reported
					limb weakness	Areflexia		
					Acroparesthesia	Later, locked in syndrome		
						Bilateral facial Palsy, Bilateral		
						hypoglossal paresis		
						Complete sensory loss		
19	Germany	Scheidl	54	Female	Paraparesis,	Proximal 3/5	PCR positive after positive	Not Reported
					Distal numbness and tingling	Distal 4/5	contact 3 weeks before. No	
					Later on, developed dysphagia	Areflexia	symptoms of cough and fever	
							However, had anosmia and	
							ageusia	
20	Iran	Ebrahimza	46	Male	Pain, and numbness in distal	Mild facial nerve palsy on the right	Sore throat, dry cough,	Not Reported
		deh- Case			lower and upper extremities for	side. Muscle Power 4/5 LL progressed	and mild dyspnea 18 days	
		1			а	to 3/5	prior to developing	
					Week followed by ascending	UL power 5/5 progressed to 4/5	neurological symptoms.	
					paralysis.	Areflexia		

21	Iran	Ebrahimza	65	Male	Ascending upper and lower	Muscle Weakness 2/5 proximal and	Fever and cough ten days	Not Reported
		deh- Case			extremity weakness and	3/5 distal UL	before	
		2			paresthesia.	UL power 4/5	PCR	
						Areflexia in lower limbs		
						UL reflexes +1		
22	USA	Chan-Case	68	Male	Gait disturbance	4/5 power hip flexors	Fever and Cough 18 days	Not Reported
		1			Paresthesia hands and feet	Absent vibratory	back	
						and proprioceptive sense at the toes		
						and areflexia in LL and present in UL		
						Later, bilateral fascial palsy,		
						dysphagia, dysarthria and neck flexion		
						weakness		
						Dysarthria and Gait problem		
23	USA	Chan -	84	Male	Paresthesia of hand and feet	Power 3/5 proximally, unable to walk	23 days before fever and	Not Reported
		Case2			07 days back	independently	cough	
					03 days gait disturbance	Gradually progressed bilateral facial		
						palsy		
						Autonomic dysfunction, areflexia in LL		
						and present in UL		
24	Spain	Caamaño	61	Male	Facial Muscles weakness	Bilateral facial nerve palsy with absent	Fever and cough without	Not reported
						blink reflex	dyspnea 10 days prior to	
						Rest of the neurological examination	admission	
						including reflexes were normal.		
		I .		1	1		1	

ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous Immunoglobulins; HRCT; High Resolution Computed Tomography scan; LL: lower limbs; ;MRC: Medical Research Council; MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper Limb

Table 2: Details of the diagnostics, management, and outcomes of COVID-19 related GBS

S/No	Country	Associated features and Co morbids	CSF / Ganglioside antibody /MRI/ CT scan findings	CT chest findings	EMG/NCS Findings	PCR for COVID-19	Respiratory failure	Mechanical Ventilation	Management	Outcomes
1.	China	Nil	Proteins 124	Ground glass	AIDP	PCR Positive on	No	No	IVIG	Discharged on day 30
			mg/dl	opacity both lungs		Day 8 of admission				with normal strength and
			Four cells							reflexes
2.	Iran	Diabetes	Not done	Diffuse	AMSAN	PCR Positive before	No	No	IVIG	Not Reported
		Mellitus		consolidation,	Day nine	admission				
				Ground glass						
				opacity and bilateral						
				pleural effusions						
3.	France	Nil	1.66 g/dl	Ground glass	AIDP	PCR Positive before	Yes	Yes	IVIG	Not Reported
			proteins and	opacity both lungs	Day five	admission				
			normal cells.							
			Ganglioside							
			antibodies							
			negative							

4.	USA	Antibiotic	Not done	Bilateral basal	Not done	Initially PCR was	Yes	Yes	IVIG	Weaned off from
		induced		opacity in lungs		positive for				Ventilator on day 4.
		colitis		Whole spine		Rhinovirus. On				Discharged to
				imaging normal		Repeat test COVID-				rehabilitation
						19 PCR was positive				
5.	Spain	Asthma	GD1b-lgG	Chest X ray normal	Not done	PCR positive	No	No	IVIG	Complete recovery at
	case 1		positive in serum							discharge. Anosmia and
			CSF analysis:							agnosia persisted
			proteins 80mg/dl							
			and 0 cells							
6.	Spain	Nil		Chest x ray normal	Not done	PCR positive	No		No	Complete recovery with
	case 2		CSF analysis: 2							no residual deficit at
			cells and 62							discharge
			mg/dl proteins							Ageusia also resolved
			CSF PCR							
			negative for							
			Covid-19							

7.	Italy	Nil	Protein level, 101 mg/dl; Cells 4 per mm3; Negative CSF	Bilateral interstitial pneumonia	AMSAN	PCR positive	Yes	Non- Invasive Ventilation	IVIG (two sessions)	Minimal improvement
			PCR Ganglioside AB negative							
8.	Italy	Nil	Proteins 123mg/dl No cells Negative CSF PCR MRI focal contrast enhancement in	CT chest was normal	AMSAN	PCR positive	No	No	IVIG	Discharged

				internal acoustic							
				meatus							
9.	Italy	, I	Nil	Proteins 193	Bilateral ground	AMAN Variant	PCR positive	Yes	Yes	IVIG two	Still critical at the time of
				mg/dl	glass opacity					sessions	publication
				No cells							Poor outcome
				Negative CSF							
				PCR							
				Ganglioside AB							
				negative							
10	. Italy	, I	Nil	Normal proteins	Normal	AIDP Variant	PCR positive	No	No	IVIG	Undergoing Rehab at the
				and no cells							time of publication
				Negative CSF							
				PCR							
11	. Italy	, 1	Nil	proteins 40mg/dl	Interstitial	AIDP Variant	PCR Negative.	Yes	Yes	IVIG followed	Patient was on ventilatory
				Cell count 3	pneumonia		Serology was			by PLEX	support at the time of
				Negative CSF			Positive for COVID-				publication
				PCR			19				

			Ganglioside Ab							
			negative							
12.	Italy	HTN, Aortic	CSf 9 cells and	Multiple bilateral	AIDP Variant	PCR positive	Yes	CPAP with	IVIG	Expired
		aneurysm	proteins 54	ground glass opacity				Prone		
		repair and	mg/dl	and consolidation				Positioning		
		lung cancer	CSF PCR							
		treated by	negative							
		surgery								
		alone								
13.	Italy		Csf proteins 48	Some ground glass	AIDP	PCR positive	Yes	Yes	IVIG	Not Reported
			mg/dl and 1 cell	areas in both lungs						
14.	USA		Not done	X ray chest Normal	Not done	PCR Positive	No	No	IVIG	Partial recovery at the
			MRI showed							time of discharge
			enhancement of							
			3 rd nerve							
			Ganglioside							
			antibody							
			negative							

15.	Switzerl		Proteins was	Chest x ray normal	AIDP	PCR Positive	No	No	IVIG	Day 11 patient
	and		raised no values							Discharged to Rehab
			provided							facility
			CSF PCR							
			negative							
			Ganglioside Ab							
			negative							
			MRI no evidence							
			of myelopathy							
16.	Morocco	rheumatoid	Proteins 1gm/l	Ground glass	AMSAN	PCR positive	No	No	IVIG	No improvement
		arthritis	and normal cells	opacity left lung						
			CSF PCR							
			negative							
17.	Italy	Mild	Proteins	Bilateral ground	Demyelination with	CSF PCR negative	Yes	Yes	IVIG	critical
		Hypertension	108mg/dl	glass opacity	axonal damage likely	Antiglycolipid e Ab				
			No cells		mixed picture	negative				
			CSF PCR							
			negative							

18.	German	Normal proteins	Bilateral interstitial	AIDP		Yes	Yes	IVIG followed	Still on mechanical
	у	9 cells in CSF.	infiltrates		Nasal swab PCR +			by PLEX	ventilation but showing
		Repeat CSF							signs of motor
		proteins high							improvement
		CSF PCR							and Undergoing
		negative							Rehabilitation
		Ganglioside AB							
		negative							
		MRI spine							
		showed							
		enhancement of							
		spinal nerve							
		roots							
19.	German	Increase	Chest X ray normal	AIDP	PCR positive	No	No	IVIG	Complete Recoverey
	у	proteins 140g/L							Discharged
		and normal cells							
		MRI cervical							
		spine is normal							

20.	Iran	Nil	78mg/dl Proteins	Multiple ground	AIDP	PCR Positive	No	No	No active	Muscle Power improved
			4 I cells	glass opacity in both					treatment	to near normal and
			Gq1b antibody	the lungs						discharged.
			negative							
			Brain and spine							
			MRI Normal							
21.	Iran	Hypertension	Not done	HRCT positive	AIDP	PCR Positive	No	No	IVIG	Muscle power improved to
			Gq1b antibody	Details not provided						4+/5. Discharged
			negative							
22.	USA		226mg/dl		Not done	PCR Positive	No	No	PLEX	Discharged to
			proteins							Rehabilitation. Can
			3 cells							ambulate with minimal
			Ganglioside Ab							assistance. Dysphagia
			negative							resolved
			CSF PCR							
			negative							

23. USA Nil	67mg/dl l	Not done	Not done	PCR Positive	Yes	Yes	PLEX	Quadriplegic with
	protein, 1 cell						followed by	intermittent autonomic
	count						IVIG	dysfunction.
	CSF PCR							Being weaned from the
	negative							ventilator
	Ganglioside Ab							
	GM2 lgG/lgM +							
24. Spain	Mildly elevated	X ray chest	Not done	PCR Positive	No	No	Low dose oral	No significant
	levels of proteins	pneumonia					Prednisolone	improvement in facial
	(44 mg/dL),							muscle weakness after 2
	absent							weeks
	leukocytes and							
	a negative PCR							
	for COVID-19							
	CT scan and							
	brain MRI							
	normal							

ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous Immunoglobulins; HRCT; High Resolution Computed Tomography scan; LL: lower limbs; ;MRC: Medical Research Council; MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper Limb

Table 3: comparison of COVID-19 associated GBS with Zika associated GBS

S No	Parameters	Zika Associated GBS – Puerto	Zika Associated GBS 48	COVID-19 associated GBS	
		Rico 44			
1.	Number of reported cases	71	23	24	
2.	Mean Age	54 Years	61 Years	60 Years	
3.	Gender Distribution females	3752.1)	8(34)	6(25%)	
4.	Facial weakness	44(62%)	9(39%)	9(37%)	
5.	Dysphagia	38(53%)	16(70%)	2(8%)	
6.	Cough	3(4.2%)		21(87%)	
7.	Shortness of breath	33(46.5%)	Not mentioned		
8.	Hyporeflexia/areflexia	71(100)	23(100%)	23(99%)	
9.	Antecedent illness to neurological signs	7 (0-21)	5.9 (1.5–6.5)	11(3-28)	
10.	Antecedent illness fever	28(39.4)	5(22%)	18(72%)	
11.	Elevated proteins in CSF	49/52(94.2%)	Not reported	16(80%)	
				Not done in 4	
				Normal in 4	
12.	ICU admission	47(66.2%)	14(61%)	9(36%)	
13.	Mechanical ventilation	22(31%)	10(43%)	9(36%)	
14.	Outcomes and discharge to rehab/nursing home	35 (49.3)	Not mentioned	3 still critical	
				2 no improvement	
				3 not reported	
15.	Discharge home	32 (45.1)	Not mentioned	16	
16.	Death	2 (2.8%)	2	1	

References

- 1. World Health Organization. Coronavirus disease (COVID-19) Situation Report 142. Available from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200610-covid-19-sitrep-142.pdf?sfvrsn=180898cd_2 Accessed, June 11, 2020.
- 2 Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China [published online ahead of print, 2020 Apr 10]. *JAMA Neurol*. 2020;e201127. doi:10.1001/jamaneurol.2020.1127
- 3. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C et.al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268-2270. doi: 10.1056/NEJMc2008597.
- 4. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A Literature Review.J Clin Neurosci 2020 May 6;S0967-5868(20)31078-X. doi: 10.1016/j.jocn.2020.05.017. Online ahead of print.
- Mathis S, Soulages A, Vallat JM, Le Masson G. History of acute polyradiculoneuropathy (part 1): The prehistory of Guillain-Barré syndrome. Neurology. 2020;94(19):828-35.
- Mathis S, Soulages A, Le Masson G, Vallat JM. History of acute
 polyradiculoneuropathy (part 2): From 1916 to 2019. Neurology 2020;94(19):836-40.
- 7. Hughes RA, Cornblath DR. Guillain-barre syndrome. The Lancet. 2005;366(9497):1653-66.

- 8. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. *J Infect Dis.* 1997;176 Suppl 2:S92-S98. doi:10.1086/513793
- 9 Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294-304.
- 10 . van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. *Nat Rev Neurol*. 2014;10(8):469-482. doi:10.1038/nrneurol.2014.121
- 11. Ansari B, Basiri K, Derakhshan Y, Kadkhodaei F, Okhovat AA. Epidemiology and Clinical Features of Guillain-Barre Syndrome in Isfahan, Iran. *Adv Biomed Res*. 2018;7:87. Published 2018 May 29. doi:10.4103/abr.abr_50_17
- 12. Willison HJ, Jacobs BC, Van Doorn PA. Guillain-barre syndrome. The Lancet. 2016;388(10045):717-27.
- 13. Khan M, Muhammad W, Nawaz K, Ahmad I, Yousaf, M, Ahmad N, Rathore F, Ahmad K. FREQUENCY OF AXONAL VARIANTS OF GUILLAIN-BARRÉ SYNDROME IN PAKISTAN. PAFMJ [Internet]. 30Sep.2011 [cited 11Jun.2020];61(3). Available from:

https://www.pafmj.org/index.php/PAFMJ/article/view/804

- 14. Wu X, Wu W, Wang Z, et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China. *PLoS One*. 2014;9(8):e104074. Published 2014 Aug 1. doi:10.1371/journal.pone.0104074
- 15. Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China. *PLoS One*. 2015;10(7):e0133520. Published 2015 Jul 22. doi:10.1371/journal.pone.0133520

- 16. Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. *Pathogens*. 2020;9(3):186. Published 2020 Mar 4. doi:10.3390/pathogens9030186
- 17. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.* 2019;17(3):181-192. doi:10.1038/s41579-018-0118-9
- 18. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the. CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci.* 2020;11(7):995-998.

doi:10.1021/acschemneuro.0c00122

- 19. Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models [published online ahead of print, 2020 Apr 25]. *Eur J Neurol*. 2020;10.1111/ene.14277. doi:10.1111/ene.14277 20. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et.al.. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection. 2015 Aug 1;43(4):495-501.
- 21. Ng Kee Kwong KC, Mehta PR, Shukla G, Mehta AR. COVID-19, SARS and MERS: A neurological perspective [published online ahead of print, 2020 May 5]. *J Clin Neurosci.* 2020;S0967-5868(20)31185-1. doi:10.1016/j.jocn.2020.04.124
- 22 . Finsterer J, Scorza FA, Ghosh R. COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid [published online ahead of print, 2020 Jun 4]. *J Med Virol*. 2020;10.1002/jmv.26121. doi:10.1002/jmv.26121
- 23. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10. PMID: 32283152; PMCID: PMC7194613.

24. Abdullahi A, Candan S, Elbol N, Olumide D. Guillian Barre syndrome in patients with COVID-19: a systematic review. PROSPERO 2020 CRD42020184822 Available

from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020184822 25. Carrillo-Larco RM, Altez-Rodriguez C. COVID-19 and Guillain-Barre syndome: a systematic review of case reports. PROSPERO 2020 CRD42020182015 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020182015 26 Padroni M, Mastrangelo V, Asioli GM, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? [published online ahead of print, 2020 Apr 24]. J Neurol. 2020;1-3. doi:10.1007/s00415-020-09849-6

- 28.Ottaviani D, Boso F, Tranquillini E, Gapeni I, Pedrotti G, Cozzio S, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci. 2020 Jun;41(6):1351-1354. doi: 10.1007/s10072-020-04449-8..

- 31. Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré Syndrome associated with SARS-CoV-2 infection [published online ahead of print, 2020 Apr 18]. IDCases. 2020;20:e00771. doi:10.1016/j.idcr.2020.e00771
- 32. Chan M, Han SC, Kelly S, Tamimi M, Giglio B, Lewis A. A case series of Guillain-Barré Syndrome following Covid-19 infection in New York. Neurology: Clinical Practice. 2020 May 20.
- 33. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020;76:233-235. doi:10.1016/j.jocn.2020.04.062
- 34. Ebrahimzadeh SA, Ghoreishi A, Rahimian N. Guillain-Barré Syndrome associated with the coronavirus disease 2019 (COVID-19). Neurology: Clinical Practice. 2020 May 20.
- 35. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R,, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19 [published online ahead of print, 2020 Apr 17. Neurology. 2020;10.1212/WNL.000000000000009619. doi:10.1212/WNL.000000000000009619
 36. Juliao Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020 May 14. doi: 10.1016/j.jocn.2020.05.016. Epub ahead of print. 37. Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature [published online ahead of print, 2020 May 10]. J Peripher Nerv Syst. 2020;10.1111/jns.12382. doi:10.1111/jns.12382

- 38. Pfefferkorn T, Dabitz R, von Wernitz-Keibel T, Aufenanger J, Nowak-Machen M, Janssen H. Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19 [published online ahead of print, 2020 May 12]. J Neurol. 2020;1-2. doi:10.1007/s00415-020-09897-y
- 39. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol.

2020;19(5):383-384. doi:10.1016/S1474-4422(20)30109-5

- 40.Camdessanche J-Philippe, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E, COVID-19 may induce Guillain-Barr 'e syndrome, Revue Neurologique (2020), doi: https://doi.org/10.1016/j.neurol.2020.04.003
- 41. Coen M, Jeanson G, Culebras Almeida LA, Hübers A, Stierlin F et.al. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun. 2020:S0889-1591(20)30698-X. doi: 10.1016/j.bbi.2020.04.074. Epub ahead of print. 42.Otmani HE, Moutawakil BE, Rafai M-Abdoh, Benna NE, Kettani CE, Soussi M, Mdaghri NE, Barrou H, Afif H, Covid-19 and Guillain-Barr ´e syndrome: More than a coincidence!, Revue Neurologique (2020), doi:

https://doi.org/10.1016/j.neurol.2020.04.007

- 43. Umapathi T. Does COVID-19 cause axonal GBS? J Clin Neurosci. 2020 May 23:S0967-5868(20)31285-6. doi: 10.1016/j.jocn.2020.05.057. Epub ahead of print. 44. Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Muñoz-Jordan JL, et all. Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA neurology. 2018 Sep 1;75(9):1089-97 45. Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurological
- complications during treatment of Middle East respiratory syndrome. Journal of Clinical Neurology. 2017 Jul 1;13(3):227-33.

- 46. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 2015;43:495-501
- 47. Zegarra-Valdivia J, Vilca BN, Tairo T, Munive V, Lastarria C. Neurological component in coronaviruses induced disease: systematic review of SARS-COV, MERS-COV, and SARS-CoV-2.

⁴⁸ Rozé B, Najioullah F, Fergé JL, Dorléans F, Apetse K, Barnay JL, Daudens-Vaysse E, Brouste Y, Césaire R, Fagour L, Valentino R. Guillain-Barré syndrome associated with Zika virus infection in Martinique in 2016: a prospective study. Clinical Infectious Diseases. 2017 Oct 16;65(9):1462-8.